Background
With an estimated 300 million individuals affected worldwide, asthma is associated with substantial social and economic burden. The cost of treating uncontrolled severe allergic asthma (SAA) is high encompassing a variety of direct medical costs and indirect costs. We present data on real-world healthcare utilization (direct) and school/work absence (indirect) in uncontrolled SAA patients receiving omalizumab in the eXpeRience registry.
Methods
eXpeRience was a 2-year, global, single-arm, observational registry. Data were collected on real-world effectiveness, safety and use of omalizumab in patients with uncontrolled SAA. Asthma-related healthcare utilization (hospitalizations, emergency room visits or unscheduled doctor visits) and number of days missed from school/work were recorded.
Results
The intent-to-treat population comprised 916 (97.1%) patients. Compared with the pre-treatment period, there were reductions in healthcare utilization and school/work absence after 12 and 24 months of omalizumab treatment.
Author information
Authors and Affiliations
Rights and permissions
Open Access This article is published under license to BioMed Central Ltd. This is an Open Access article is distributed under the terms of the Creative Commons Attribution License ( https://creativecommons.org/licenses/by/2.0 ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
About this article
Cite this article
Braunstahl, GJ., Deenstra, M., Canvin, J. et al. Healthcare utilization and indirect cost of treatment associated with severe allergic asthma in a real-world setting. Clin Transl Allergy 3 (Suppl 1), P1 (2013). https://doi.org/10.1186/2045-7022-3-S1-P1
Published:
DOI: https://doi.org/10.1186/2045-7022-3-S1-P1